Obesity is a chronic disease which has now become a worldwide phenomenon. The factors sourcing obesity are numerous but the prime factor being excessive intake of food. Obesity is not only a health risk in itself but encompasses other health …
Rimonabant acomplia is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Obesity is now the most common nutritional disorder in western countries. …
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines.[1] …
Research demonstrates effectiveness of treatments for childhood obesity and early signs of PCOS in girls. New research findings presented this week in New Orleans during ENDO 2004, the 86th Annual Meeting of The Endocrine Society, could help keep kids healthier. …
Rimonabant is certified for the treatment of predominance.
According to whether humans are actively (work, sport) or relaxed and passive (meal, sleep), the bodily functions are regulated by different parts unconscious nervous systems.
A part of this system is the Endocannabinoid in …